NextFin News - A Dutch court has rejected an investor request to open an investigation into Royal Philips over its 2021 sleep apnea device recall, a ruling that removes one of the last governance-level threats hanging over the Dutch medical-technology group even as criminal probes in France and the United States remain open.
The Enterprise Chamber of the Amsterdam Court of Appeal denied the petition brought by the Dutch Shareholders' Association (VEB) and a group of institutional investors, declining to order an inquiry into Philips' policy and course of affairs. The decision, dated Saturday, is a procedural victory for Philips but does not end the legal overhang from a recall that at one point erased roughly two-thirds of the company's market value and triggered more than $1 billion in settlements.
The ruling draws a line under the Dutch governance chapter of the crisis while leaving the harder questions - criminal liability, regulatory sanctions, and the company's ability to rebuild its US respiratory business - to other courts and agencies.
What the Investors Asked For, and What the Court Declined
The VEB filed its petition in September 2025, joined by asset manager Vanguard along with pension funds and insurers. The investor group argued that Philips' "failing information provision" had produced misleading annual reports, press releases and other public disclosures in the years surrounding the recall. The group sought the appointment of an independent official at Philips to oversee potential settlement talks and to address alleged conflicts of interest involving Chief Executive Roy Jakobs, who previously led the division responsible for the apnea devices.
The remedy the investors pursued is distinctive to Dutch corporate law and deliberately narrow in its consequences. The Enterprise Chamber's inquiry procedure allows shareholders to ask for an independent investigation into a company's policy and conduct when there are reasonable grounds to doubt the correctness of that policy. Even if granted, the procedure does not itself result in fines or compensation against the company. What it can do is force transparency: an appointed investigator reconstructs what management knew, when it knew it, and whether disclosures were timely.
"Investor confidence has been seriously damaged. There is a great importance for all concerned that offences do not stay shrouded in the mist, lessons are learnt, and responsibility is taken," the VEB said in a statement when it launched the initiative.
Philips rejected the allegations from the start. A company spokesperson said shareholders were interpreting disclosures with the benefit of hindsight, that there were no clear signals of elevated health risks before the recall, that complaint levels remained limited, and that the recall itself did not prove a systemic failure in the company's internal systems.
The court's rejection indicates the petitioners did not meet the high threshold the Enterprise Chamber applies to inquiry requests. Philips said it would defend its position, and the company has consistently maintained that it acted responsibly throughout the crisis.
The decision follows a similar outcome for the VEB just days earlier. On Wednesday, the same chamber dismissed a VEB petition seeking an inquiry into OCI N.V. and ordered the investor group to pay administrative costs estimated at approximately €18,000. Two defeats in three days suggest the chamber is applying a strict gate to inquiry requests, even in cases involving serious allegations.
The Recall That Shrank a Medtech Giant
The crisis dates to June 14, 2021, when Philips Respironics, a subsidiary of Royal Philips, issued a voluntary recall notification in the United States and a field safety notice internationally for certain continuous positive airway pressure (CPAP), bilevel PAP (BiPAP) and mechanical ventilator devices. The problem lay in the polyester-based polyurethane (PE-PUR) sound-abatement foam inside the machines, which could break down and release particles or chemicals that users might inhale or swallow. Regulators and clinicians warned of potential respiratory irritation and, with long-term exposure, cancer risk.
The scale was enormous. The US Food and Drug Administration, in announcing the permanent injunction and consent decree that took effect in April 2024, cited 15 million devices impacted worldwide. The recall forced millions of sleep apnea patients to decide whether to continue therapy on potentially defective machines or stop treatment altogether - a dilemma that carried its own health risks for people dependent on nightly breathing support.
The market reaction was immediate and severe. Shares fell $2.25, or 3.98%, on the day the recall was announced, and over the following years fears of open-ended litigation bills lopped off roughly two-thirds of Philips' market value at the trough. The company's response - a multi-year remediation program, a change of chief executive, and a series of settlements - has been aimed at capping that liability and restoring the US business.
The largest single resolution came in April 2024, when Philips agreed to pay $1.1 billion to settle all personal injury claims filed in the United States, alongside a separate settlement of the economic-loss class action. At the time, analysts at Barclays called the figure "significantly lower than expectations of $2-4 billion and worst case of $10 billion," and the stock rallied on the news.
The Financial Picture: Recovery Under Way, But Not Complete
Philips' most recent quarterly results show a company emerging from the worst of the crisis, though the scars remain visible. In the second quarter of 2026, reported in late July, group sales reached €4.4 billion, reflecting 4% comparable sales growth across all business segments. Adjusted EBITA margin expanded to 16.4%, but that headline figure included a US tariff refund benefit worth roughly 4.2 percentage points; on an underlying basis the margin was 12.2%. Income from operations was €609 million, including the €186 million tariff refund benefit.
The company used the improved momentum to raise its full-year guidance: comparable sales growth of 3% to 4.5%, an adjusted EBITA margin of 13.5% to 14.0%, and free cash flow of €1.5 billion to €1.7 billion, updated to reflect the tariff refund.
Beneath the quarterly improvement, the annual damage is still evident. For the full year 2024, Philips reported a net loss of €698 million, wider than the €463 million loss in 2023, as the company continued to absorb recall-related costs and weaker demand in China. Nominal sales declined 1% for the year, with revenue just over $18 billion.
On the remediation front, Philips has made substantial progress. The company reported that it has remediated 99% of actionable sleep therapy device registrations globally. In the United States, 2.683 million patients had been remediated out of 2.691 million actionable registrations as of early February 2026, and as of July 6 the company had completed all steps required by the US Recall Remediation Plan for sleep therapy devices. Ventilator remediation remains ongoing, coordinated through durable medical equipment providers.
What the Ruling Changes - and What It Does Not
The Enterprise Chamber decision is best understood as a shift in the battlefield rather than an end to the war. By declining to appoint an independent investigator, the court has removed the one mechanism that could have produced a court-supervised, third-party reconstruction of Philips' internal decision-making in the years before the recall. Management now retains full control over the narrative and the document flow in the remaining proceedings.
That matters because the remaining legal exposure is substantial and sits outside Dutch civil procedure. In France, prosecutors are investigating charges of aggravated fraud and failure to report safety risks - a criminal track that the Enterprise Chamber inquiry could never have touched. In the United States, the Department of Justice continues criminal and civil investigations, the Securities and Exchange Commission maintains its own probe, and attorneys general in 41 states are pursuing separate inquiries. The FDA's permanent injunction, entered as part of the April 2024 consent decree, continues to constrain Philips' ability to manufacture and sell respiratory devices in the US market.
The distinction is important for investors weighing the stock. A Dutch governance loss for the VEB does not reduce the probability of a French indictment, a US criminal settlement, or an extended period of restricted US sales. What it does is remove a parallel channel of pressure and eliminate the risk that an appointed investigator would uncover evidence usable in those other forums.
Market Read: Priced for Caution, Not for Celebration
The market has not treated the remediation progress and improving margins as a reason to re-rate the shares. Philips' stock closed at $24.24 on Friday, down 0.82% on the day, with a market capitalization of about $23.7 billion. The shares are trading near the bottom of their 52-week range of $23.62 to $33.44 and below the 50-day average of $25.80 - a positioning that suggests investors are still discounting the unresolved regulatory path rather than celebrating the governance win.
That caution is consistent with a market that has been burned before. The recall destroyed roughly two-thirds of the company's value at its worst point, and the recovery since the April 2024 settlement has been partial and uneven. Investors appear to be waiting for concrete evidence that the US respiratory business can be restored under FDA supervision before assigning the stock a higher multiple.
The distinction between cyclical and structural damage is the crux of the investment question. The recall shock itself was cyclical: a product-harm crisis with a defined remediation path that is now 99% complete for sleep therapy devices, and its financial impact is mean-reverting as settlements are capped and margins recover. The structural damage is narrower but more durable - the FDA's permanent injunction has reshaped Philips' US manufacturing footprint, and the loss of the Respironics franchise's pre-recall standing in the world's largest sleep therapy market may not fully reverse on its own. The ruling removes a cyclical overhang; it does not repair the structural one.
The Counter-Case: A Procedural Win Is Not a Clean Bill of Health
The strongest argument against reading too much into Friday's ruling is straightforward: it resolves almost nothing that can still hurt the company. French prosecutors are still pursuing aggravated fraud and failure-to-report charges. The US Department of Justice, the SEC, and 41 state attorneys general continue their investigations. The FDA injunction still blocks full US market access. None of these proceedings was affected by the Enterprise Chamber's decision, and any one of them could produce penalties, restrictions, or reputational damage far larger than a Dutch inquiry ever could have.
There is force in that view, but it misses what the inquiry procedure uniquely threatened. The Enterprise Chamber's power is not to fine; it is to illuminate. An appointed investigator with statutory authority could have compelled testimony and documents, reconstructed the timeline of internal warnings, and published findings that would have been discoverable in the French and American cases. By keeping that mechanism out of play, Philips has preserved its ability to manage the flow of information in the proceedings that remain.
The falsifying signal for the view that the overhang is lifting is concrete: if French prosecutors bring formal charges against Philips executives, or if the US Department of Justice files criminal charges against the company or its managers, the thesis that the worst of the legal risk is behind Philips would be wrong. A second falsifier would be an SEC enforcement action alleging disclosure violations tied to the pre-recall period - precisely the allegation the VEB could not get the Enterprise Chamber to investigate.
What to Watch Next
Three time horizons frame the path from here. In the short term, the removal of the governance overhang could support a relief rally in shares that have been oversold relative to the improving quarterly results. In the medium term, the key variable is the US respiratory business: Philips' ability to restore manufacturing and sales under the consent decree will determine whether the margin recovery is durable or dependent on one-time tariff benefits. In the long term, the structural question is whether the Respironics franchise can regain its pre-recall position in the US sleep therapy market, or whether the brand damage and the FDA's heightened oversight have permanently impaired the business.
Scenarios diverge sharply. In the base case, the French probe and US investigations conclude without executive charges, and Philips gradually restores its US sales footprint under FDA supervision. In the upside case, the Department of Justice reaches a settlement lighter than the market fears and the company returns to full US market participation sooner than expected. In the downside case, French criminal charges or a US criminal enforcement action reopen the liability question and extend the company's exclusion from its largest market.
Investors should watch for three specific signals: any filing by French prosecutors indicating formal charges; the terms and timing of any DOJ or SEC resolution; and Philips' own milestones for restoring US manufacturing and sales under the consent decree.
The court's refusal closes the chapter on what Philips knew and when it knew it - at least in the Netherlands. The chapters still open are about what regulators will do about it, and those are the ones that will decide whether this stock is a recovery story or a cautionary tale.
Explore more exclusive insights at nextfin.ai.
